Abstract
SARS-CoV-2 has had an unprecedented impact on human health and highlights the need for genomic epidemiology studies to increase our understanding of the evolution and spread of pathogens and to inform policy decisions. We sequenced viral genomes from over 22,000 patients tested at Mayo Clinic Laboratories between 2020-2022 and leveraged detailed patient metadata to describe county and regional spread in Minnesota via Bayesian phylodynamics. We found that spread in the state was mostly dominated by viruses from Hennepin County, which contains the state’s largest metropolis. This includes the spread of earlier clades as well as variants of concern Alpha and Delta. Ramsey County, the second most populated county had its greatest impact later in the pandemic during variants of concern Alpha, Delta, and early Omicron.
The earliest introduction into Minnesota was to Hennepin from a domestic (USA) source on around January 23, 2020; six weeks before the first confirmed case in the state. The first county-to-county introductions were estimated to originate from Hennepin to somewhere in Central Minnesota around February 28 and from Hennepin to bordering Ramsey County around March 1. Both international and domestic introductions were most abundant in Hennepin (home to an international airport). Hennepin also was, by far, the most dominant source of in-state transmissions to other Minnesota locations (n=1,832) over the two-year period.
We measured the ratio of introductions to total viral flow into and out of each county/region. A value of 1 suggests a location as being a “sink” (accepts SARS-CoV-2 lineages but never exports them to other counties), while a value of 0 indicates a county as being a “source”. Most locations were “sinks” throughout the pandemic. Central Minnesota (outside of Hennepin and Ramsey) was dominated by introductions early, but later in 2020 and early 2021 experienced brief fluctuating trends of higher virus exportation. Hennepin showed a different trend than all others as it consistently acted as a source for other Minnesota counties. However, there were brief periods of fluctuation such as an increase in the ratio of introductions towards the end of 2020 and early 2021, potentially driven by introductions from international locations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This publication was supported by funding from the Center for Individualized Medicine-Mayo Clinic Research. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Number R01AI164481 (to MS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted under approval of ethics by the Mayo Clinic Institutional Review Board and assigned a study ID IRB#: 20-005896 and entitled Large Scale Whole Genome Sequencing of SARS-CoV-2. All our published datasets contain randomly generated study IDs and no personal identifiers. All data analysis was performed behind the Mayo Clinic firewall.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
We have deposited the SARS-CoV-2 genomes and metadata from this study in GISAID with a list available at doi.org/10.55876/gis8.220720me. The Minnesota Department of Health sequences used in this study are available on GISAID with acknowledgments at doi.org/10.55876/gis8.220709mv. Our GenBank international sequences were identified via the Nextstrain [20] site and obtained from NCBI Virus [2]. We have deposited BEAST XML files and our empirical set of posterior .trees file in figshare at doi.org/10.6084/m9.figshare.21777995.v1, doi.org/10.6084/m9.figshare.21778004.v1, doi.org/10.6084/m9.figshare.21777998.v1.